A 36-year-old Japanese man was hospitalized with coughing and exertional dyspnea (NYHAclass I). He was diagnosed as having congestive heart failure, and was treated with diuretics and a p-adrenergic blocking agent. He responded well to the treatment and his symptomscompletely disappeared within a few days. Based on his clinical, laboratory, and molecular genetic findings, he was diagnosed as having X-linked dilated cardiomyopathy (XLDCM). He was found to have a large deletion in the dystrophin gene, involving exons 45-55. This is the first report on a Japanese XLDCM patient with a mutation in the central hot-spot region of this gene.
Introduction
X-linked dilated cardiomyopathy (XLDCM) is a rare cardiospecific phenotype of dystrophinopathy which presents as lethal congestive heart failure in teenage males without overt clinical signs of skeletal myopathy (1) . Onthe other hand, some female carriers of XLDCM show dilated cardiomyopathy with later onset and slower progression than affected males. Until now, 13 different mutations in the dystrophin gene have been reported in XLDCMpatients (2) (3) (4) (5) (6) (7) (8) (9) (10) , but the precise pathogenesis of this unique phenotype has remained unclear. It was first thought that mutations responsible for XLDCM were centered at the 5' end of the dystrophin gene (2-A), but increasing awareness of XLDCM has led to the identification of some patients with mutations outside the 5' end of the gene (5) (6) (7) (8) (9) (10) . This report describes a Japanese patient with XLDCM who carried a large deletion involving exons 45-55 of the dystrophin gene. This is the first report of a Japanese XLDCM patient with a mutation in the central hot-spot region of this gene. We have tentatively classified XLDCM patients into three groups according to the region of the mutations. Wealso briefly discuss the phenotype-genotype correlation in XLDCM.
Case Report
A previously healthy 36-year-old Japanese man was admitted to our hospital in September 1999 because of coughing and exertional dyspnea (NYHAclass I) following commoncoldlike symptoms. He had no specific disease history and had not taken any medication. There was no family history of neuromuscular disease ( Fig. 1 ). His mother and younger sister were apparently well and blood chemistry findings of the mother were all within normal limits. On admission, he was slightly obese (170 cm, 86 kg), and his body temperature was 36.9°C, blood pressure 126/100 mmHg,and heart rate 1 16 beats/min with a regular rhythm.
Coarse crackles were heard in the lower lung fields, but no heart murmurwas audible. Abdominal and neurological examination results were not remarkable. Thechest roentgenogram revealed slight cardiomegaly (cardiothoracic ratio 60%), bilateral pleural effusion, and pulmonary congestion ( Fig. 2A ).
The electrocardiogram showed sinus tachycardia, poor R-wave progression in leads V,-V3 and flat T wave in leads I, aVL, V5 and V6 (Fig. 3A) . The echocardiogram showed left ventricular dilatation (LVDd 72 mm), diffuse hypokinesis of the left ventricular wall motion ( Fig. 3B ) and reduced cardiac output (EF 16%). Laboratory findings are summarized in Table 1 .
The patient was diagnosed as having congestive heart failure due to dilated cardiomyopathy, and was treated with furosemide (40 mg/day), spironolactone (25 mg/day), enalapril (5 mg/day), and carvedilol (5 mg/day). Continuous administration of catecholamine was not needed. Thepatient responded well to the treatment and recovered completely within a few ddys. On day 10 after admission, cardiomegaly decreased (cardiothoracic ratio 55%), and bilateral pleural effusion and pulmonary congestion completely disappeared on the chest roentgenogram ( Fig. 2B ). On day 15 after admission, cardiac catheterization, including endomyocardial biopsy from the right ventricle, was performed. The coronary arteriogram showed no significant stenotic lesions in either the left or right coronary artery. The mean pulmonary capillary wedge pressure was 18 mmHg,left ventricular end-diastolic pressure was 1 3 mmHg, and the cardiac index was 1.7 //min. The left ventriculogram showeddilatation of the left ventricle cavity and a reduced ejection fraction (1 1%) ( Fig. 4A, B ). Microscopic examination of a biopsy specimen showed myocyte degeneration, irregularly shaped nuclei and interstitial fibrosis, all of which were compatible with a diagnosis of dilated cardiomyopathy ( Fig. 4C ). Because of insufficient specimen, Azan staining or immunostaining us-ing anti-dystrophin antibodies could not be performed.
Since the presence of elevated serum creatine phosphokinase (CK) and its dominant MMisoform brought to mind systemic muscle disease as a cause of dilated cardiomyopathy, analysis of the dystrophin gene was performed after informed consent was obtained. PCRand Southern blotting analyses of genomic DNAextracted from peripheral leukocytes confirmed that the patients carried a deletion in the dystrophin gene, ranging from exon 45 to 55 ( Fig. 5 ). Exons 44 and 56 were detected as intact by Southern blotting. On the basis of these clinical, laboratory, and molecular genetic findings, the patient was definitively diagnosed as having XLDCM. His mother was diagnosed as a heterozygous carrier by Southern blot analysis (data not shown). Table 2 shows sequential changes in echocardiographic parameters, plasma levels of brain natriuretic peptide (BNP) and serum CK, indicating gradual improvement in his condition. Seventeen months after the onset, the patient is free from any symptoms.
Discussion
XLDCM was first described by Berko and Swift in 1987 in a large kindred in which dilated cardiomyopathy, with or without congestive heart failure, was seen in ll young men and three middle-aged women (1) . In 1993, Towbin et al showed that dystrophin was greatly reduced in cardiac muscle, but not in skeletal muscle, of patients from the family described by Berko and Swift (1 1). Furthermore, Muntoni et al first identified a mutation in the dystrophin gene in patients from another XLDCMfamily (2). These findings have confirmed that XLDCM is a cardiospecific phenotype of dystrophinopathy. The genetic defect in the dystrophin gene generally causes Duchenne/Becker muscular dystrophy (DMD/BMD), which shows progressive skeletal myopathy, often accompanied by cardiomyopathy. The most significant difference between DMD/BMD and XLDCM is that cardiac muscle is preferentially affected in the latter. As a result, skeletal myopathy is not evident in XLDCM.
Initially it was thought that mutations of the dystrophin gene responsible for XLDCMgathered at the 5' end of the gene (2-4), but it is now known that mutations in XLDCM patients are more heterogeneous than previously expected (5-10). To date, 14 different mutations (including the one described in this study) have been identified in the dystrophin gene in XLDCMpatients (2-10). Based on the region of the mutations, patients with XLDCM can be classified into the following three groups ( Table 3) : those with mutations in the 5' end of the gene (Group I), in the central hot-spot region (12) (13) (14) (15) (16) , centered around exon 48-49 (Group II) and in regions other than those of Group I or II (Group III). The precise pathogenesis of XLDCM has remained unclear, but it is obvious that the frame-shift hypothesis (13) cannot explain the XLDCMphenotype; this is because differences in the transcription pattern and functions of dystrophin between skeletal and cardiac muscles are not taken into consideration in the frame-shift hypothesis. Amongthese three groups, the pathogenetic mechanisms have been most intensively investigated in Group I. In Group I patients, the dystrophin muscle isoform, the most predominant isoform of this protein, is absent in both skeletal and cardiac muscles (2) (3) (4) 17) . Instead, the brain and Purkinje-cell isoforms are compensatively upregulated in skeletal muscle, but not in cardiac muscle (2-^, 17) . Because of its unique tissue-specific pattern of transcription of dystrophin isoforms, we here separate Group I from the other groups. There is no explanation as to whycardiac muscle is preferentially affected in Group II patients. Since the incidence of cardiac involvement is high in BMDpatients with deletions involving exon 49, but not in those with deletions of only exon 48 (18, 19) , it has been proposed that intron 48 might contain sequences important to the function of dystrophin in cardiac muscle (5, 20) . But there is no further information on these kinds of sequences. Mutant dystrophin transcripts have not been well characterized in Group II patients, but all the deletions so far identified in these patients are in-frame and are typically associated with mild BMD ( 15) . In fact, immunohistochemical and Western blot analyses on Group II patients have shown that although dystrophin expression is reduced in cardiac muscle, it is preserved (5, 6) . In contrast, cardiac dystrophin was completely absent, or severely reduced in Group I or III patients (2, 3, 7, 9, 1 1). Therefore, we speculate that the pathophysiological basis of dilated cardiomyopathy is different in Group II compared to Group I or III patients.
In terms of the clinical aspect, patients in Group II tend to showa later onset and a slower progression than those in Groups I or III (Table 3 ). In addition, the increase in serum creatinine kinase seems to be less prominent and familial occurrence is less frequent in patients in Group II than in those in the other 3, 4, 6, 8, 17, 19, 44, 45, 48, 49, 50, 52 , and 60) were individually amplified (12, 14, 16) . 100 ng of genomic DNAwere used for each PCR reaction. PCRproducts were separated on a 3% agarose gel and stained with ethidium bromide. (B): Southern blot analysis. Genomic DNA(5 jig) was digested with Hind III, separated on 1 %agarose gel, and blotted onto a nylon membrane. 32P-labelled dystrophin CDNA fragments were used as probes for hybridization. Exons ranging from 45 to 55 were deleted in our patient. Lane 1: our patient; 2: male control; 3: female control. two groups (Table 3) . Thus, XLDCMpatients with mutations in the central hot-spot region mayerroneously be diagnosed as not having dystrophinopathy.
Arbustini et al screened 201 consecutive male patients in Italy with dilated cardiomyopathy for dystrophin defects and found that only 4 (about 2%) met the clinical criteria for XLDCM (6) . Furthermore, Shiga et al reported that dystrophin defects were not identified in 92 Japanese patients with dilated cardiomyopathy (2 1 ). Therefore, mutation in the dystrophin gene is an uncommon cause of dilated cardiomyopathy. Although only two families with XLDCM have been reported in Japan (4), it is important to examine patients for dystrophin abnormalities, especially young males with dilated cardiomyopathy, because proper genetic counseling is very often needed for the family membersin cases of dystrophinopathy. Dystrophin immunostaining of biopsy samples from cardiac and/or skeletal muscles should be the first step of diagnosis for such patients. The dystrophin gene should be analyzed for patients with abnormal immunostaining, or when no biopsy samples are available.
